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Abstract
This review deals with the application of a new prefractionation tool, free-ﬂow
electrophoresis (FFE), for proteomic analysis of colorectal cancer (CRC). CRC is a
leading cause of cancer death in the Western world. Early detection is the single most
important factor inﬂuencing outcome of CRC patients. If identiﬁed while the disease
is still localized, CRC is treatable. To improve outcomes for CRC patients there
is a pressing need to identify biomarkers for early detection (diagnostic markers),
prognosis (prognostic indicators), tumour responses (predictive markers) and disease
recurrence (monitoring markers). Despite recent advances in the use of genomic
analysis for risk assessment, in the area of biomarker identiﬁcation genomic methods
alone have yet to produce reliable candidate markers for CRC. For this reason,
attention is being directed towards proteomics as a complementary analytical tool
for biomarker identiﬁcation. Here we describe a proteomics separation tool, which
uses a combination of continuous FFE, a liquid-based isoelectric focusing technique, in
the ﬁrst dimension, followed by rapid reversed-phase HPLC (1–6 min/analysis) in the
second dimension. We have optimized imaging software to present the FFE/RP-HPLC
data in a virtual 2D gel-like format. The advantage of this liquid based fractionation
system over traditional gel-based fractionation systems is the ability to fractionate
large quantity protein samples. Unlike 2D gels, the method is applicable to both
high-Mr proteins and small peptides, which are difﬁcult to separate, and in the case
of peptides, are not retained in standard 2D gels. Copyright  2005 John Wiley &
Sons, Ltd.
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Epidemiology of colorectal cancer (CRC)
CRC is one of the most common cancers diagnosed
each year in Western countries, accounting for
13–14% of all cancer presentations [1,2] and for
10–13% of all cancer deaths [1,2]. The major
impetus for research into markers of CRC is that,
if detected early, when tumours are still localized
[3], the projected 5 year survival rate is ∼90%.
Unfortunately, most colorectal cancers (∼60%)
present at an intermediate stage with a concomitant
decrease in survival rates [2]. The majority of
colorectal cancers (65–85%) are sporadic in nature,
the result of cumulative somatic mutations [4]. Up
to 30% of patients have a family history of bowel
cancer, of which 6% belong to clearly deﬁned
familial genetic syndromes, such as hereditary
non-polyposis colon cancer (HNPCC) and familial
adenomatous polyposis (FAP). Of the sporadic
risk factors, age is the most important, with the
incidence increasing exponentially after age 50 [5].
Colorectal carcinomas arise from adenomas (also
referred to as polyps), hence the ‘adenoma–carci-
noma sequence’, with a lag time of ∼10 years
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[4,6,7], and the removal of these polyps has been
shown to prevent colorectal cancer [7].
Current detection methods for CRC
In the USA, UK and Australia, the general rec-
ommended screening regimen involves annual to
biennial faecal occult blood tests (FOBT) and 5-
yearly sigmoidoscopies [8,9]. However, effective
population screening by these means is precluded
by patient compliance, due to discomfort and lack
of awareness of the epidemiology of colorectal can-
cer. If used alone, FOBT has been shown to be
ineffective [10]. This type of screening is not diag-
nostic of CRC, but merely selects those patients
who should proceed to colonoscopy.
The most widely used blood-based protein bio-
marker of CRC, carcinoembryonic antigen (CEA),
exhibits poor sensitivity for screening for the early
detection of the disease and is mainly employed in
post-operative detection for recurrence and moni-
toring of metastasis [11,12]. Whilst a single marker
may lack sensitivity and speciﬁcity for detec-
tion, combining markers improves these parameters
[13,14].
Proteomics tools
Current proteomics research can be deﬁned as
two contrasting but complementary strategies, cell-
mapping proteomics and protein expression pro-
teomics [15,16].
Cell-mapping proteomics
Cell-mapping proteomics aims to deﬁne pro-
tein–protein interactions to build a picture of the
complex networks that constitute intracellular sig-
nalling pathways. Many genetic mutations associ-
ated with cancer progression affect genes encod-
ing proteins in signalling pathways, highlighting
the importance of deﬁning these signalling net-
works [17]. For example, Pandey et al. treated
HeLa cells with either epidermal growth factor or
platelet-derived growth factor (PDGF), and used
anti-phosphotyrosine immunoprecipitation to con-
centrate a range of proteins that were subsequently
phosphorylated [18]. The analysis revealed the role
of vav-2, as well as a number of other proteins,
in growth factor signalling. Alternatively, Lewis
et al. selectively activated or inhibited the mitogen-
activated protein kinase (MAPK) pathway and used
a proteomic approach to identify 20 novel targets of
MAPK signalling [19]. Afﬁnity capture techniques
have also been used to identify the anti-apoptotic
protein DIABLO/SMAC [20] and binding proteins
for suppressors of cytokine signalling, SOCS [21].
Although the scope of this review does not cover
the full range of possibilities available, these few
examples show the utility of cell-mapping pro-
teomics.
Protein-expression proteomics
Protein expression analysis monitors global expres-
sion of large numbers of proteins within a cell type
or tissue and quantitatively identiﬁes how patterns
of expression change in different circumstances.
Global protein proﬁles can be produced for normal
compared with tumour cells in a given tissue, or
for cells before and after treatment with a speciﬁc
drug. Currently, this is the most widely used model
of proteomics and is largely dependent upon two-
dimensional gel electrophoresis (2DE) for visual-
ization of protein proﬁles. Expression proteomics
is the protein equivalent of DNA microarray anal-
ysis. Like DNA microarrays, it has the advantage of
being non-prejudicial and could deﬁne unexpected
ways in which known proteins regulate cellular
responses. Major limitations of the 2DE system
include an inability to detect proteins of medium
to low abundance, as well as a limited appar-
ent molecular mass range (Mr), where molecules
smaller than 10 K are generally lost. This has
prompted much interest in non-2DE approaches for
studying global protein proﬁles.
Correlation of mRNA transcripts and
protein expression levels
In the search for tumour progression markers or
anticancer drug targets, there has been a concerted
effort to deﬁne gene expression proﬁles at the tran-
script level [22,23]. However, it is clear that mRNA
expression data alone are insufﬁcient to predict
functional outcomes for the cell, as they provide
very little information about activation state, post-
translational modiﬁcation or localization of corre-
sponding proteins. Moreover, there are numerous
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reports highlighting the disparity between mRNA
transcript and protein expression levels [24,25].
Thus, at the very least, mRNA expression stud-
ies must be supported with proteomic information
in an integrated approach to provide a complete
picture of how cells are altered during malignant
transformation [25,26].
Dynamic range of protein abundances
Several technical issues need to be addressed
before proteomics can realize its full potential for
protein expression proﬁling of complex proteomes
such as cells and tissues [27,28]. Foremost is the
problem of dynamic range of protein abundances.
For instance, the dynamic range of protein abun-
dances in blood is thought to be ∼1010 [29]. This
makes it extremely challenging to visualize low-
abundance proteins and peptides in complex pro-
teomes such as blood, let alone identify them using
current mass spectrometry (MS)-based identiﬁca-
tion methods [30–32]. For example, the most abun-
dant protein in human plasma is serum albumin
(HSA), present at 40–50 mg/ml, whereas some of
the least abundant proteins, such as cytokines [33]
and protease biomarkers (e.g. the prostate-speciﬁc
antigen [34]), are present at ∼10 and ∼3 pg/ml
levels, respectively. Given that the current sen-
sitivity of routine protein and peptide identiﬁca-
tion by MS–MS is ∼500 amol, in order to obtain
500 amol of IL-6, approximately ∼1.5m lp l a s m a
would be required for the initial fractionation step.
However, this amount of plasma would also contain
1.4 µM (90 mg) HSA, which is 6.2 × 109 (w/w)
in excess of IL-6. This is a formidable quantity
of protein to fractionate and presents a challenge
to current puriﬁcation schemes, where extensive
pre-fractionatation/depletion strategies need to be
invoked in order to reveal low-abundance pro-
teins. However, this also assumes that the pro-
tein of interest is homogenous and a 100% recov-
ery is obtained through all fractionation steps.
For IL-6, which is extensively post-translationally
modiﬁed (pI range 5–7, Mr range 22–29 K
[33,35,36]), much larger quantities of plasma
would be required to obtain a single enriched popu-
lation of IL-6 molecules for identiﬁcation purposes.
Of equal importance is the problem that proteins
exhibit tremendous heterogeneity with respect to
size, charge, post-translational modiﬁcations and
solubility. Consequently, a wide range of protein
separation methods, or combinations thereof, i.e.
multidimensional separation strategies, are usually
required for the comprehensive analysis of complex
proteomes.
For several decades, 2DE [37,38] has been the
only proteomics technique that has permitted the
separation of thousands of proteins in a single
experiment [39,40]. However, the dynamic range of
protein abundances that can be separated by 2DE is
∼104, which is inadequate for cell types and tissues
such as blood.
Prefractionation approaches in
proteome analysis
Several approaches for overcoming the protein
dynamic range obstacle have been recently descri-
bed, viz. (a) the disassembly of the macromolec-
ular architecture of cells into their constituent
organelles, macromolecular structures and multi-
protein complexes allowing subproteome analysis
[41,42]; (b) enrichment of cellular components
using differential detergent fractionation [43,44] or
molecular weight fractionation [45]; (c) depletion
of abundant proteins using non-biospeciﬁc chro-
matography [46], immunoafﬁnity chromatography
using speciﬁc antibodies against abundant proteins
[47], and removal of IgG from serum using
immobilized protein-A or — G columns [48–52];
(d) selective precipitation, e.g. with triﬂuoracetic
acid/acetone [53] prior to 2DE; and (e) various
chromatographic [54,55] and electrophoretic meth-
ods [56].
Prefractionation of proteins from large volumes,
as a prelude to subsequent analysis using 2DE,
can be performed by preparative polyacrylamide
gel electrophoresis (PAGE) or size-exclusion chro-
matography on the basis of Mr [57,58]. Alterna-
tive electrophoretic prefractionation methods based
upon solution-phase IEF, rather than gel-based IEF
[59] used in 2DE, have been developed. These
non-gel-based IEF methods can accommodate large
sample volumes and amounts in contrast to gel-
based IEF methods. Preparative IEF as a prefrac-
tionation technique was ﬁrst proposed by Bier’s
laboratory [60,61]. To overcome problems asso-
ciated with the original device, Righetti and col-
leagues [62] developed a multicompartment elec-
trolyser in which each compartment was separated
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Figure 1. Schematic representation of the continuous FFE apparatus coupled off-line to RP-HPLC. Dimensions of focusing
chamber: 50 × 10 × 0.04 cm (10 cm between electrodes, 45 cm electrode length). For analytical imaging separations, a
portion of each ﬁrst-dimension FFE-IEF fraction (50 µl/total volume ∼2 ml) was injected directly from the 96 deep-well
plate using the Agilent 1100 HPLC equipped with a well-plate autosampler and samples collected automatically into a
multi-plate fraction collection system
by a polyacrylamide gel membrane, each with a
deﬁned pH. A microscale liquid-phase IEF pre-
fractionation method that is also based upon a
multicompartment apparatus (4.7 ml total volume,
650 µl/chamber) has recently been described by
Speicher et al. [63]. In this apparatus the chambers
are separated by thin polyacrylamide gels contain-
ing ampholyte mixtures at speciﬁc pH values. For a
recent review of prefractionation techniques in pro-
teome analysis, see Righetti et al. [64] and Simpson
[28].
Free-ﬂow electophoresis (FFE)
FFE, ﬁrst described by Hannig, [65,66], is a sep-
aration device that continuously streams a sam-
ple into a carrier ampholine solution ﬂowing as a
thin laminar ﬁlm (0.3–1.0 mm) between two ﬂat
plates (see Figure 1). By introducing an electric
ﬁeld perpendicular to the direction of ﬂow, cellu-
lar organelles, proteins and low Mr species such
as peptides can be separated by IEF according
to their different pI values and subsequently col-
lected for further analysis [67,68]. Previously, we
reported an uncoupled FFE-IEF/SDS-PAGE strat-
egy for separating cytosolic proteins from a human
colon carcinoma cell line for subsequent identiﬁ-
cation by on-line RP-HPLC/electrospray-ionization
(ESI)-ion trap MS [69]. We have further reﬁned
this strategy to provide a complete liquid-based
fractionation strategy by introducing off-line rapid
RP-HPLC (1–6 min separation times) as a sec-
ond dimension for each of the FFE fractions. An
example of a complex protein separation, such as a
cell lysate, using this method is shown in Figure 2.
Unlike 2DE, this technique is suitable for separat-
ing low-Mr proteins and polypeptides and does not
have the problem of sample loadability, due to the
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Figure 2. Two-dimensional FFE-IEF/RP-HPLC separation of cytosolic proteins from untreated and non-steriod
anti-inﬂammatory drug (NSAID)-treated human LIM 1215 colorectal cell line. (A) Sample: 1 mg untreated LIM 1215
cytosolic proteins dissolved in 1 ml IEF running buffer containing 0.2% (w/v) HPMC, 0.4% (v/v) Servalyte pH 3–10 loaded
at 1.4 ml/h at 1500 V, 15 mA and collected into a deep 96-well plate. Second dimension RP-HPLC separation of FFE-IEF
fraction. (B) Sample: 1 mg NSAID-treated LIM1215 cytosolic proteins. FFE-IEF and second dimension RP-HPLC separation
are as in (A); proteins indicated by arrows were dysregulated by NSAID treatment of LIM 1215 cells (R.L. Moritz,
manuscript in preparation)
ease by which the method can accommodate large
sample volumes [70]. FFE can be performed over
both broad and narrow ranges of pH by the judi-
cious choice of ampholytes in the ﬁrst dimension
step. Additionally, we have developed software to
present the chromatographic output as a single 2D
plot (virtual 2D analysis) for quick visual evalua-
tion and ‘spot’ matching of fractionated proteins.
The ability to fractionate low-Mr compounds
is an important feature of this 2D liquid-based
FFE-IEF/RP-HPLC method, because techniques
designed for this purpose are under represented
in the armory of current proteomic separation
tools. 2D gel-based systems, multicompartment and
column-based separation systems are also limited
by the quantity of bulk starting material that can be
loaded in the ﬁrst dimension (IPG). This limitation
in fractionation of starting material can hamper
efforts to mine complex tissues.
The advantages of this system can be summa-
rized as follows: (a) protein and/or peptide separa-
tions in the ﬁrst dimension (IEF) are performed in
a liquid phase and, unlike other multicompartment
electroanalysers, are not restricted by passaging
through any barrier or matrix; (b) the system is
truly preparative by not being sample-limited, and
separation efﬁciency is maintained by continual
ﬂushing of the separated sample; and (c) the FFE-
IEF/RP-HPLC system is capable of separating
compounds of low Mr (e.g. peptides) as well as
high Mr (e.g. native proteins and their multimeric
complexes) over a broad pH range. For those pro-
teins (especially membrane proteins) that exhibit
poor solubility at or near their pI value, an appro-
priate buffer (e.g. amino acids as well as detergents
in the case of membrane protein separations) can
be incorporated in the FFE counterﬂow media prior
to collection in the 96-well plate to minimize the
time that such proteins stand at their pI value
[69]. The high-resolving power produced in the
ﬁrst dimension IEF step, where very narrow range
pH gradients can easily be generated, coupled to
the high resolution of modern RP-HPLC station-
ary phases, extends the resolving power of this
2D protein separation system over other previously
described 2D systems based solely on coupled
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HPLC columns [71,72]. In the case of high-Mr pro-
teins and very hydrophobic proteins such as mem-
brane proteins, the RP-HPLC stationary phases can
be substituted by other chromatographic modes,
such as hydrophobic interaction chromatography
or hydroxyapatite stationary phases to extend the
power of the method to cover classes of proteins
that are refractory to RP chromatography.
The advantage of the 2D liquid-based FFE/RP-
HPLC system over traditional gel-based systems is
that complex mixtures of low-Mr compounds, such
as tryptic peptides, can be fractionated, whereby
peptides are fractionated into discrete pools with
increasing pH values that vary one from another by
∼0.02 pH units. The ease and rapid determination
of the apparent peptide pI value can be achieved
by measuring the pH of these pools using a lab-
oratory combination pH electrode. By applying a
peptide’s pI determinant to high mass accuracy
(1 ppm) peptide-mass ﬁngerprinting, [73–75] the
discrimination of peptides differing by small mass
units or even isobaric peptides is feasible [76].
Peptide mass, as determined by current high mass
accuracy mass spectrometers, by itself as the only
parameter for peptide identiﬁcation in large genome
databases, is insufﬁcient for high-conﬁdence pro-
tein identiﬁcation and is no longer considered a
valid approach to protein identiﬁcation by the edi-
tors of proteomics journals [77]. The use of a pep-
tide’s pI value combined with MS–MS data also
provides a powerful qualiﬁer for peptide identiﬁca-
tions, as well as decreasing the peptide search pool.
The latter can be achieved by minimizing the num-
ber of peptides used to search with, by only con-
sidering those peptides that are within a discrete pI
range in conjunction with the mass range deﬁned
by the accuracy of the mass spectrometer used.
Concluding remarks
The 2D liquid based FFE-IEF/RP-HPLC method
described here promises to play a key role in
the analysis of complex protein and low-Mr com-
pounds, the latter being largely under repre-
sented in most proteome studies to date. Interest-
ingly, low-Mr proteins and peptides are thought
to contain a rich source of previously undiscov-
ered biomarkers of disease [78]. Although current
claims regarding the potential of proteomics to
deﬁne cancer-related molecules might outnumber
reports of concrete achievement, both global-
expression [79,80] and cell-mapping proteomics
[19–21] have contributed to our understanding of
cell biology and disease. To date, several proteins
have been identiﬁed from colon tumour samples
and patient blood that can potentially be used for
biomarkers for the identiﬁcation of early onset col-
orectal cancer [81,82]. Validation of these identi-
ﬁcations must be performed before these proteins
can be ascribed as diagnostic biomarkers [83]. It
is anticipated that further proteomics studies aimed
at identifying speciﬁc proteins present in biological
specimens of diseased patients may reveal a panel
of proteins that correlate with aberrant growth spe-
ciﬁc or individual cancer subtypes. When used in
combination, such a cohort of biomarkers may pro-
vide for a high-sensitivity and -speciﬁcity predic-
tive assay with minimal invasion to the patient,
thereby allowing for population-based screening.
Acknowledgement
Funding was provided by the Australian National Health
and Medical Research Council under Program Grant No.
280912.
References
1. Australian Institute of Health and Welfare (AIHW) &
Australasian Association of Cancer Registries (AACR)
(ed). 2003. Cancer in Australia 2000. AIHW: Canberra;
http://www.aihw.gov.au
2. American Cancer Society (ed). 2004. Cancer Facts and
Figures. American Cancer Society: Atlanta; http://www.
cancer.org
3. Etzioni R, Urban N, Ramsey S, et al. 2003. The case for early
detection. Nat Rev Cancer 3: 243–252.
4. Fearon ER, Vogelstein B. 1990. A genetic model for colorectal
tumorigenesis. Cell 61: 759–767.
5. Chung DC. 2000. The genetic basis of colorectal cancer:
insights into critical pathways of tumorigenesis. Gastroenterol-
ogy 119: 854–865.
6. Fearon ER. 1994. Molecular genetic studies of the ade-
noma–carcinoma sequence. Adv Intern Med 39: 123–147.
7. Winawer SJ, Zauber AG, Ho MN, et al. 1993. Prevention of
colorectal cancer by colonoscopic polypectomy. The National
Polyp Study Workgroup. N Engl J Med 329: 1977–1981.
8. Cancer Research UK (ed). 2004. Large Bowel Cancer
Factsheet; http://www.cancerresearchuk.org
9. American Cancer Society (ed.) 2004. Cancer Facts & Figures.
American Cancer Society: Atlanta, GA.
10. Collins JF, Lieberman DA, Durbin TE, Weiss DG. 2005.
Accuracy of screening for fecal occult blood on a single stool
sample obtained by digital rectal examination: a comparison
with recommended sampling practice. A n nI n t e r nM e d142:
81–85.
Copyright  2005 John Wiley & Sons, Ltd. Comp Funct Genom 2005; 6: 236–243.242 R. L. Moritz et al.
11. Crawford NP, Colliver DW, Galandiuk S. 2003. Tumor
markers and colorectal cancer: utility in management. J Surg
Oncol 84: 239–248.
12. Duffy MJ, van Dalen A, Haglund C, et al. 2003. Clinical
utility of biochemical markers in colorectal cancer: European
Group on Tumour Markers (EGTM) guidelines. Eur J Cancer
39: 718–727.
13. Holten-Andersen MN, Christensen IJ, Nielsen HJ, et al. 2002.
Total levels of tissue inhibitor of metalloproteinases 1 in
plasma yield high diagnostic sensitivity and speciﬁcity in
patients with colon cancer. Clin Cancer Res 8: 156–164.
14. Hall NR, Finan PJ, Stephenson BM, Purves DA, Cooper EH.
1994. The role of CA-242 and CEA in surveillance following
curative resection for colorectal cancer. Br J Cancer 70:
549–553.
15. Blackstock WP, Weir MP. 1999. Proteomics: quantitative and
physical mapping of cellular proteins. Trends Biotechnol 17:
121–127.
16. Simpson RJ, Dorow DS. 2001. Cancer proteomics: from
signaling networks to tumor markers. Trends Biotechnol 19:
S40–S48.
17. Downard J. 2001. The ins and outs of signalling. Nature 411:
759–762.
18. Pandey A, Podtelejnikov AV, Blagoev B, et al. 2000. Anal-
ysis of receptor signaling pathways by mass spectrometry:
identiﬁcation of vav-2 as a substrate of the epidermal and
platelet-derived growth factor receptors. Proc Natl Acad Sci
USA 97: 179–184.
19. Lewis TS, Hunt JB, Aveline LD, et al. 2000. Identiﬁcation of
novel MAP kinase pathway signaling targets by functional
proteomics and mass spectrometry. Mol Cell 6: 1343–1354.
20. Verhagen AM, Ekert PG, Pakusch M, et al. 2000. Identiﬁca-
tion of DIABLO, a mammalian protein that promotes apop-
tosis by binding to and antagonizing IAP proteins. Cell 102:
43–53.
21. Zhang JG, Farley A, Nicholson SE, et al. 1999. The con-
served SOCS box motif in suppressors of cytokine signal-
ing binds to elongins B and C and may couple bound pro-
teins to proteasomal degradation. Proc Natl Acad Sci USA 96:
2071–2076.
22. Ross DT, Scherf U, Eisen MB, et al. 2000. Systematic
variation in gene expression patterns in human cancer cell
lines. Nat Genet 24: 227–235.
23. Scherf U, Ross DT, Waltham M, et al. 2000. A gene
expression database for the molecular pharmacology of cancer.
Nat Genet 24: 236–244.
24. Gygi SP, Rochon Y, Franza BR, Aebersold R. 1999. Correla-
tion between protein and mRNA abundance in yeast. Mol Cell
Biol 19: 1720–1730.
25. Tian Q, Stepaniants SB, Mao M, et al. 2004. Integrated
genomic and proteomic analyses of gene expression in
mammalian cells. Mol Cell Proteom 3: 960–969.
26. Cox B, Kislinger T, Emili A. 2005. Integrating gene and
protein expression data: pattern analysis and proﬁle mining.
Methods 35: 303–314.
27. Simpson RJ. 2003. Proteins and Proteomics: A Laboratory
Manual. Cold Spring Harbor Laboratory Press: Cold Spring
Harbor, NY.
28. Simpson RJ. 2004. Purifying Proteins for Proteomics: A
Laboratory Manual. Cold Spring Harbor Laboratory Press:
Cold Spring Harbor, NY.
29. Anderson NL, Polanski M, Pieper R, et al. 2004. The human
plasma proteome: a non-redundant list developed by
combination of four separate sources. Mol Cell Proteomics.
3: 311–326.
30. Domon B, Alving K, He T, Ryan TE, Patterson SD. 2002.
Enabling parallel protein analysis through mass spectrometry.
Curr Opin Mol Ther 4: 577–586.
31. Patterson SD. 2003. Proteomics: evolution of the technology.
Biotechniques 35: 440–444.
32. Ferguson PL, Smith RD. 2003. Proteome analysis by mass
spectrometry. Annu Rev Biophys Biomol Struct 32: 399–424.
33. Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward
LD. 1997. Interleukin-6: structure–function relationships.
Protein Sci 6: 929–955.
34. Balk SP, Ko YJ, Bubley GJ. 2003. Biology of prostate-
speciﬁc antigen. J Clin Oncol 21: 383–391.
35. Van Snick J, Cayphas S, Vink A, et al. 1986. Puriﬁcation
and NH2-terminal amino acid sequence of a T-cell-derived
lymphokine with growth factor activity for B-cell hybridomas.
Proc Natl Acad Sci USA 83: 9679–9683.
36. Van Snick J, Vink A, Cayphas S, Uyttenhove C. 1987.
Interleukin-HP1, a T cell-derived hybridoma growth factor
that supports the in vitro growth of murine plasmacytomas.
JE x pM e d165: 641–649.
37. O’Farrell PH. 1975. High resolution two-dimensional elec-
trophoresis of proteins. JB i o lC h e m250: 4007–4021.
38. Klose J. 1975. Protein mapping by combined isoelectric
focusing and electrophoresis of mouse tissues. A novel
approach to testing for induced point mutations in mammals.
Humangenetik 26: 231–243.
39. Gorg A, Obermaier C, Boguth G, et al. 2000. The current
state of two-dimensional electrophoresis with immobilized pH
gradients. Electrophoresis 21: 1037–1053.
40. Lottspeich F. 1999. Proteome analysis: a pathway to the
functional analysis of proteins. Angewandte Chem Int Ed 38:
2477–2492.
41. Jung E, Heller M, Sanchez JC, Hochstrasser DF. 2000.
Proteomics meets cell biology: the establishment of subcellular
proteomes. Electrophoresis 21: 3369–3377.
42. Brunet S, Thibault P, Gagnon E, et al. 2003. Organelle
proteomics: looking at less to see more. Trends Cell Biol 13:
629–638.
43. Ramsby ML, Makowski GS, Khairallah EA. 1994. Differen-
tial detergent fractionation of isolated hepatocytes: biochemi-
cal, immunochemical and two-dimensional gel electrophoresis
characterization of cytoskeletal and noncytoskeletal compart-
ments. Electrophoresis 15: 265–277.
44. Ramsby ML, Makowski GS. 1999. Differential detergent
fractionation of eukaryotic cells. Analysis by two-dimensional
gel electrophoresis. Methods Mol Biol 112: 53–66.
45. Ji H, Baldwin GS, Burgess AW, et al. 1993. Epidermal
growth factor induces serine phosphorylation of stathmin in
a human colon carcinoma cell line (LIM 1215). JB i o lC h e m
268: 13396–13405.
46. Travis J, Pannell R. 1973. Selective removal of albumin
from plasma by afﬁnity chromatography. Clin Chim Acta 49:
49–52.
47. Pieper R, Su Q, Gatlin CL, et al. 2003. Multi-component
immunoafﬁnity subtraction chromatography: an innovative
step towards a comprehensive survey of the human plasma
proteome. Proteomics 3: 422–432.
Copyright  2005 John Wiley & Sons, Ltd. Comp Funct Genom 2005; 6: 236–243.FFE/RP-HPLC: a proteomics fractionation tool 243
48. Bjorck L, Kronvall G. 1981. Analysis of bacterial cell wall
proteins and human serum proteins bound to bacterial cell
surfaces. Acta Pathol Microbiol Scand B 89: 1–6.
49. Bjorck L, Kronvall G. 1984. Puriﬁcation and some properties
of streptococcal protein G, a novel IgG-binding reagent. J
Immunol 133: 969–974.
50. Akerstrom B, Brodin T, Reis K, Bjorck L. 1985. Protein G:
a powerful tool for binding and detection of monoclonal and
polyclonal antibodies. J Immunol 135: 2589–2592.
51. Guss B, Eliasson M, Olsson A, et al. 1986. Structure of the
IgG-binding regions of streptococcal protein G. EMBO J 5:
1567–1575.
52. Govorukhina NI, Keizer-Gunnink A, van der Zee AGJ, et al.
2003. Sample preparation of human serum for the analysis
of tumor markers — comparison of different approaches for
albumin and γ-globulin depletion. J Chromatogr A 1009:
171–178.
53. Gorg A, Boguth G, Obermaier C, Weiss W. 1998. Two-
dimensional electrophoresis of proteins in an immobilized pH
4–12 gradient. Electrophoresis 19: 1516–1519.
54. Washburn MP, Wolters D, Yates JR III. 2001. Large-scale
analysis of the yeast proteome by multidimensional protein
identiﬁcation technology. Nat Biotechnol 19: 242–247.
55. Wu CC, MacCoss MJ. 2002. Shotgun proteomics: tools for
the analysis of complex biological systems. Curr Opin Mol
Ther 4: 242–250.
56. Righetti PG, Castagna A, Antonioli P, Boschetti E. 2005.
Prefractionation techniques in proteome analysis: the mining
tools of the third millennium. Electrophoresis 26: 297–319.
57. Zugaro LM, Reid GE, Ji H, et al. Characterization of
rat brain stathmin isoforms by two-dimensional gel
electrophoresis–matrix-assisted laser desorption/ionization
and electrospray ionization-ion trap mass spectrometry.
Electrophoresis 19: 867–876.
58. Fountoulakis M, Juranville JF. 2003. Enrichment of low-
abundance brain proteins by preparative electrophoresis. Anal
Biochem 313: 267–282.
59. Bjellqvist B, Ek K, Righetti PG, et al. 1982. Isoelectric
focusing in immobilized pH gradients: principle, methodology
and some applications. J Biochem Biophys Methods 6:
317–339.
60. Egen NB, Bliss M, Mayersohn M, et al. 1988. Isolation of
monoclonal antibodies to phencyclidine from ascites ﬂuid by
preparative isoelectric focusing in the Rotofor. Anal Biochem
172: 488–494.
61. Bier M, Long T. 1992. Recycling isoelectric focusing: use of
simple buffers. J Chromatogr 604: 73–83.
62. Faupel M, Barzaghi B, Gelﬁ C, Righetti PG. 1987. Isoelectric
protein puriﬁcation by orthogonally coupled hydraulic and
electric transports in a segmented immobilized pH gradient.
J Biochem Biophys Methods 15: 147–161.
63. Zuo X, Speicher DW. 2002. Comprehensive analysis of com-
plex proteomes using microscale solution isoelectrofocusing
prior to narrow pH range two-dimensional electrophoresis.
Proteomics 2: 58–68.
64. Righetti PG, Castagna A, Herbert B, Reymond F, Rossier JS.
2003. Prefractionation techniques in proteome analysis.
Proteomics 3: 1397–1407.
65. Hannig K. 1961. Die Tragerfreie Kontinuierliche Elek-
trophorese und Ihre Anwendung. Fresenius Zeitschr Anal
Chem 181: 244–274.
66. Hannig K, Heidrich HG. 1990. Free-ﬂow Electrophoresis.G I T
Verlag GmbH: Darmstadt, Germany.
67. Burggraf D, Weber G, Lottspeich F. 1995. Free ﬂow-
isoelectric focusing of human cellular lysates as sam-
ple preparation for protein analysis. Electrophoresis 16:
1010–1015.
68. Zischka H, Weber G, Weber PJ, et al. 2003. Improved
proteome analysis of Saccharomyces cerevisiae mitochondria
by free-ﬂow electrophoresis. Proteomics 3: 906–916.
69. Hoffmann P, Ji H, Moritz RL, et al. 2001. Continuous free-
ﬂow electrophoresis separation of cytosolic proteins from
the human colon carcinoma cell line LIM 1215: a non
two-dimensional gel electrophoresis-based proteome analysis
strategy. Proteomics 1: 807–818.
70. Moritz RL, Ji H, Schutz F, et al. 2004. A proteome strategy
for fractionating proteins and peptides using continuous
free-ﬂow electrophoresis coupled off-line to reversed-phase
high-performance liquid chromatography. Anal Chem 76:
4811–4824.
71. Bushey MM, Jorgenson JW. 1990. Automated instrumenta-
tion for comprehensive two-dimensional high-performance
liquid chromatography of proteins. Anal Chem 62: 161–167.
72. Wagner K, Racaityte K, Unger KK, et al. 2000. Protein
mapping by two-dimensional high performance liquid
chromatography. J Chromatogr A 893: 293–305.
73. Henzel WJ, Billeci TM, Stults JT, et al. 1993. Identifying
proteins from two-dimensional gels by molecular mass
searching of peptide fragments in protein sequence databases.
Proc Natl Acad Sci USA 90: 5011–5015.
74. Pappin DJC, Hojrup P, Bleasby AJ. 1993. Rapid identiﬁcation
of proteins by peptide-mass ﬁngerprinting. Curr Biol 3:
327–332.
75. Henzel WJ, Watanabe C, Stults JT. 2003. Protein identiﬁca-
tion: the origins of peptide mass ﬁngerprinting. J Am Soc Mass
Spectrom 14: 931–942.
76. Cargile BJ, Stephenson JL. 2003. An alternative to tandem
mass spectrometry: isoelectric point and accurate mass for the
identiﬁcation of peptides. Anal Chem 76: 267–275.
77. Baldwin MA. 2004. Protein identiﬁcation by mass spectrom-
etry: issues to be considered. Mol Cell Proteom 3: 1–9.
78. Liotta LA, Ferrari M, Petricoin E. 2003. Clinical proteomics:
written in blood. Nature 425: 905.
79. Celis JE, Ostergaard M, Rasmussen HH, et al. 1999. A
comprehensive protein resource for the study of bladder
cancer: http://biobase.dk/cgi-bin/celis. Electrophoresis 20:
300–309.
80. Celis JE, Wolf H, Ostergaard M. 2000. Bladder squamous cell
carcinoma biomarkers derived from proteomics. Electrophore-
sis 21: 2115–2121.
81. Nam MJ, Kee MK, Kuick R, Hanash SM. 2004. Identiﬁcation
of defensin α6 as a potential biomarker in colon
adenocarcinoma. JB i o lC h e m280: 8260–8265.
82. Albrethsen J, Bogebo R, Gammeltoft S, et al. 2005. Upregu-
lated expression of human neutrophil peptides 1, 2 and 3 (HNP
1–3) in colon cancer serum and tumours: a biomarker study.
BMC Cancer (in press).
83. Ransohoff DF. 2005. Lessons from controversy: ovarian
cancer screening and serum proteomics. J Natl Cancer Inst
97: 315–319.
Copyright  2005 John Wiley & Sons, Ltd. Comp Funct Genom 2005; 6: 236–243.